231 related articles for article (PubMed ID: 19190348)
1. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.
Edukulla R; Woller N; Mundt B; Knocke S; Gürlevik E; Saborowski M; Malek N; Manns MP; Wirth T; Kühnel F; Kubicka S
Cancer Res; 2009 Feb; 69(4):1448-58. PubMed ID: 19190348
[TBL] [Abstract][Full Text] [Related]
2. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
4. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
5. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
6. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
7. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
8. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.
Sang H; Pisarev VM; Chavez J; Robinson S; Guo Y; Hatcher L; Munger C; Talmadge CB; Solheim JC; Singh RK; Talmadge JE
Cancer Gene Ther; 2005 Apr; 12(4):427-37. PubMed ID: 15678151
[TBL] [Abstract][Full Text] [Related]
9. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. No defect in T-cell priming, secondary response, or tolerance induction in response to inhaled antigens in Fms-like tyrosine kinase 3 ligand-deficient mice.
Walzer T; Brawand P; Swart D; Tocker J; De Smedt T
J Allergy Clin Immunol; 2005 Jan; 115(1):192-9. PubMed ID: 15637568
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
13. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
14. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
[TBL] [Abstract][Full Text] [Related]
15. Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect.
Nakano A; Yoneyama H; Ueha S; Kitabatake M; Ishikawa S; Kawase I; Sugiyama H; Matsushima K
Int Immunopharmacol; 2007 Jun; 7(6):845-57. PubMed ID: 17466918
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of MIP-1alpha-recruited dendritic cells on preestablished solid and metastatic tumors.
Cao Q; Jin Y; Jin M; He S; Gu Q; He S; Qiu Y; Ge H; Yoneyama H; Zhang Y
Cancer Lett; 2010 Sep; 295(1):17-26. PubMed ID: 20202744
[TBL] [Abstract][Full Text] [Related]
17. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
18. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.
Zou W; Luo C; Zhang Z; Liu J; Gu J; Pei Z; Qian C; Liu X
Oncogene; 2004 Jan; 23(2):457-64. PubMed ID: 14724574
[TBL] [Abstract][Full Text] [Related]
19. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus.
Komaru A; Ueda Y; Furuya A; Tanaka S; Yoshida K; Kato T; Kinoh H; Harada Y; Suzuki H; Inoue M; Hasegawa M; Ichikawa T; Yonemitsu Y
J Immunol; 2009 Oct; 183(7):4211-9. PubMed ID: 19734206
[TBL] [Abstract][Full Text] [Related]
20. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection.
Solheim JC; Reber AJ; Ashour AE; Robinson S; Futakuchi M; Kurz SG; Hood K; Fields RR; Shafer LR; Cornell D; Sutjipto S; Zurawski S; LaFace DM; Singh RK; Talmadge JE
Cancer Gene Ther; 2007 Apr; 14(4):364-71. PubMed ID: 17235356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]